Business

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Haduvio met the primary endpoint with a statistically-significant reduction

Trevi Therapeutics, Inc.March 10, 20254
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

About this update from Trevi Therapeutics, Inc.

Haduvio met the primary endpoint with a statistically-significant reduction (p

View stock analysis, news, and events for Trevi Therapeutics, Inc.

More from Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

August 26, 2026

Trevi Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

August 6, 2026

All Trevi Therapeutics, Inc. news →